Pricing Log in Create free account

BioMarin Pharmaceutical Inc. (BMRN) vs Summit Therapeutics PLC (SMMT)

BioMarin Pharmaceutical Inc. and Summit Therapeutics PLC are both Biotechnology companies. Summit Therapeutics PLC is the larger, with a market value of $12.3B against $10.9B — 1.1× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; BioMarin Pharmaceutical Inc. trades at 144×. BioMarin Pharmaceutical Inc. grew revenue faster over the last twelve months: 11.2% against −61.0%. BioMarin Pharmaceutical Inc. has the higher net margin (2.14% vs 0.00%) and the higher return on invested capital (0.97% vs 0.00%). Across the 19 metrics below, BioMarin Pharmaceutical Inc. leads on 15 and Summit Therapeutics PLC on 4.

Valuation

Metric BMRN SMMT Biotechnology median
P/E 143.89 n/m 8.50
P/S 3.10 16,148.72 9.71
P/B 1.67 18.07 2.13
Price to free cash flow 14.59 n/m 20.82
EV/EBITDA 46.69 n/m 0.64
EV/Sales 4.08 15,310.43 9.21
Earnings yield 0.69% (7.66%) (33.15%)
Free cash flow yield 6.85% (4.04%) (25.50%)

Profitability

Metric BMRN SMMT Biotechnology median
Gross margin 76.12% 100.00% 65.16%
Operating margin 4.38% 0.00% 0.00%
Net margin 2.14% 0.00% 0.00%
Free cash flow margin 21.28% 0.00% 0.00%
Return on equity 1.18% (192.50%) (56.36%)
Return on assets 0.76% (159.09%) (48.04%)
Return on invested capital 0.97% 0.00% 0.00%

Growth

Metric BMRN SMMT Biotechnology median
Revenue growth (TTM) 11.20% (61.03%) 6.02%
EPS growth (last fiscal year) (18.55%) (364.52%) 30.26%
Revenue growth, 5-year CAGR 11.60% (46.49%) 9.41%
Net income growth, 5-year CAGR (16.39%) 0.00% 0.00%

Health

Metric BMRN SMMT Biotechnology median
Debt to equity 0.66 0.00 0.00
Current ratio 2.39 6.96 4.72
Net debt to EBITDA (1.99) 0.65 0.96

Dividend

Metric BMRN SMMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BMRN SMMT Biotechnology median
Market cap 10.85b 12.26b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack